A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension

References

• Ingelsson E, Sullivan LM, Fox CS, et al. Burden and prognostic importance of subclinical cardiovascular disease in overweight and obese individuals. Circulation 2007;116:375–84
   PubMed Web of Science ®Google Scholar
• Mikhail N, Golub MS, Tuck ML. Obesity and hypertension. Prog Cardiovasc Dis 1999;42:39–58
   PubMed Web of Science ®Google Scholar
• Brown CD, Higgins M, Donato KA, et al. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 2000;8:605–19
   PubMedGoogle Scholar
• Garrison RJ, Kannel WB, Stokes J, et al. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 1987;16:235–51
   PubMed Web of Science ®Google Scholar
• Bramlage P, Pittrow D, Wittchen HU, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004;17:904–10
   PubMed Web of Science ®Google Scholar
• Calle EE, Thun MJ, Petrelli JM, et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med 1999;341:1097–105
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–72. Erratum in: JAMA 2003;290: 197
   Google Scholar
• Tuck ML, Sowers J, Dornfeld L, et al. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. NEJM 1981;304:930–3
   PubMed Web of Science ®Google Scholar
• Engeli S, Bohnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 2005;45:356–62
   PubMed Web of Science ®Google Scholar
• Messerli FH, Christie B, DeCarvalho JG, et al. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med 1981;141:81–5
   Google Scholar
• Hall JE, Brands MW, Dixon WN, et al. Obesity-induced hypertension. Renal function and systemic hemodynamics. Hypertension 1993;22:292–9
   Google Scholar
• de Simone G, Wachtell K, Palmieri V, et al. Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy. The LIFE (Losartan Intervention For Endpoint reduction in hypertension) study. Circulation 2005;111:1924–31
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003
   Google Scholar
• Lindholm LH, Ibsen H, Dahlöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004–10
   Google Scholar
• Kizer JR, Dahlöf B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol. The Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 2005;45:46–52
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of newonset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002;20:1879–86
   Google Scholar
• Devereux RB, de Faire U, Fyhrquist F, et al. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy. Curr Med Res Opin 2007;23:259–70
   PubMed Web of Science ®Google Scholar
• Goldstein LB, Adams R, Becker K, et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001;32:280–99
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937–52
   PubMed Web of Science ®Google Scholar
• Moan A, Hoieggen A, Nordby G, et al. Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity? J Hum Hypertens 1995;9:545–50
   Google Scholar
• Paolisso G, Tagliamonte MR, Gambardella A, et al. Losartanmediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens 1997;11:307–12
   PubMed Web of Science ®Google Scholar
• Moan A, Risanger T, Eide I, et al. The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension. Blood Press 1994;3:185–8
   PubMedGoogle Scholar
• Aksnes TA, Reims HM, Guptha S, et al. Improved insulin sensitivity with the angiotensin II‑receptor blocker losartan in patients with hypertension and other cardiovascular risk factors. J Hum Hypertens 2006;20:860–6
   PubMed Web of Science ®Google Scholar
• Cheetham C, O’Driscoll G, Stantons K, et al. Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in type I diabetes. Clin Sci 2001; 100:13–7
   PubMed Web of Science ®Google Scholar
• Cheetham C, Collis J, O’Driscoll G, et al. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol 2000;36: 1461–6
   Google Scholar
• Deng YB, Yang HY, Li CL, et al. Angiotensin receptor antagonist losartan improves endothelial function of epicardial coronary arteries in patients with essential hypertension. Clin Cardiol 2002;25:422–8
   PubMed Web of Science ®Google Scholar
• Deng YB, Wang DW, Li CL, et al. Effects of angiotensin receptor antagonist losartan on the response of the left main coronary artery to cold pressor test in patients with essential hypertension as assessed by echocardiography. Can J Cardiol 2002;18:389–96
   PubMed Web of Science ®Google Scholar
• Erdem Y, Usalan C, Haznedaroglu IC, et al. Effects of angiotensin converting enzyme and angiotensin II receptor inhibition on impaired fibrinolysis in systemic hypertension. Am J Hypertens 1999;11:1071–6
   Google Scholar
• Graninger, M, Reiter R, Drucker C, et al. Angiotensin receptor blockade decreases markers of vascular inflammation. J Cardiovasc Pharmacol 2004;44:335–9
   PubMed Web of Science ®Google Scholar
• Makris TK, Stavroulakis G, Papadopoulos DP, et al. Eprosartan effect on fibrinolytic/hemostatic variables in arterial hypertension: a comparative study to losartan. Drugs Exp Clin Res 2004;3:125–32
   Google Scholar
• Prasad A, Tupas-Habib T, Schenke WS, et al. Acute and chronic angiotensin‑1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000;101:2349–54
   PubMed Web of Science ®Google Scholar
• White M. Cardioprotective effect of angiotensin II receptor antagonists. Can J Cardiol 1999;15:10F–4
   Google Scholar
• Fliser D, Buchholz K, Haller H; EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110: 1103–7
   Google Scholar
• Milne GL, Sanchez SC, Musiek ES, et al. Quantification of F2-isoprotanes as a biomarker of oxidative stress. Nat Protoc 2007;2:221–6
   PubMed Web of Science ®Google Scholar
• Jordan J, Engeli S, Boye SW, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007;49:1047–55
   PubMed Web of Science ®Google Scholar
• Jordan J, Engeli S, Boschmann M, et al. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients. J Hypertens 2005;23:2313–8
   PubMed Web of Science ®Google Scholar
• Reisin E, Weir MR, Falkner B, et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997; 30:140–5
   PubMed Web of Science ®Google Scholar
• de Simone G, Palmieri V, Bella JN, et al. Association of left ventricular hypertrophy with metabolic risk factors: the HyperGEN study. J Hypertens 2002;20:323–31
   PubMed Web of Science ®Google Scholar
• Xu H J, Barnes GT, Yang O, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112:1821–30
   PubMed Web of Science ®Google Scholar
• Wellen KE, Hotamisligil GS. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest 2003;112:1785–8
   PubMed Web of Science ®Google Scholar
• De Michele M, Panico S, Iannuzzi A, et al. Association of obesity and central fat distribution with carotid artery wall thickening in middle-aged women. Stroke 2002;33:2923–8
   PubMed Web of Science ®Google Scholar
• Fox CS, Massaro JM, Hoffman U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007;116:39–48
   PubMed Web of Science ®Google Scholar
• Rahmouni K, Correia ML, Haynes WG, et al. Obesity-associated hypertension: new insights into mechanisms. Hypertension 2005;45:9–14
   PubMed Web of Science ®Google Scholar
• Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131–5
   PubMed Web of Science ®Google Scholar
• Traupe T, Lang M, Goettsch W, et al. Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens 2002;20:2239–45
   PubMed Web of Science ®Google Scholar
• Ridker PM, Danielson E, Rifai N, et al. Valsartan, blood pressure reduction, and C‑reactive protein: primary report of the Val-MARC trial. Hypertension 2006;48:73–9
   PubMed Web of Science ®Google Scholar
• Festa A, D’Agostino R Jr, Williams K, et al. The relation of body fat mass and distribution to markers of chronic inflammation. Intl J Obes Rel Metab Disord 2001;25:1407–15
   PubMed Web of Science ®Google Scholar
• Kramer C, Sunkomat J, Witte J, et al. Angiotensin II receptorindependent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002;90:770–6
   PubMed Web of Science ®Google Scholar
• Schmidt B, Schieffer B. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites. J Med Chem 2003;46:2261–70
   Google Scholar
• Katugampola SD, Davenport AP. Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan. Br J Pharmacol 2001;134:1385–92
   PubMed Web of Science ®Google Scholar
• Ibsen H, Olsen MH, Wachtell K, et al. Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabetes Care 2006;29:595–600
   PubMed Web of Science ®Google Scholar